Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Live webinar: Navigating new frontiers: Ways to find space in the future RA market

March 1, 2019 | Pharma, RA, healthcare, webinar 

In partnership with pharmaphorum

Thursday 21st March 2019
15:00 GMT / 16:00 CET

Register now to secure your place »

The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several other candidates reach late-stage development.

Analysis of Therapy Watch data, a real-time’ syndicated market tracking tool from Research Partnership, shows that JAK inhibitors have already made a strong impression in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake.

This pharmaphorum webinar, held in conjunction with Research Partnership, will use the latest intelligence from both physicians and patients to look at emerging trends in the RA market, how these will shape the RA market of tomorrow and how companies can best position themselves for future success.

Focus
The webinar will be held on Thursday 21st March from 15:00-16:00 GMT and will provide an opportunity to interact with the panel about how companies can best harness the potential of this increasingly complex, but highly rewarding, market.

Topics to be covered include:

  • The European RA market
  • Current status and market situation of JAK inhibitors (key EU5 countries)
  • Uptake curve of JAKs compared to other new entrants and biosimilars
  • Profile of physicians prescribing JAKS
  • Country differences
  • The future of new classes of JAK inhibitors

Thursday 21st March 2019
15:00 GMT / 16:00 CET

Register now to secure your place »

This content was provided by Research Partnership

Company Details

- PMLiVE

Research Partnership

Email
Website

 Latest Content from  Research Partnership 

Article: Spotlight on Mexico

Healthcare under AMLO – One year on

News: Mandira Kar joins London Headquarters as Qualitative Research Director

Research Partnership are delighted to announce that Mandira Kar has joined as a Qualitative Research Director. Mandira is an expert in ethnography with over 15 years’ experience in market research,...

Announcing a change of leadership at the US Philadelphia office

Research Partnership’s Philadelphia office is announcing a change of leadership from the start of 2020. President Harriet Kozak will be stepping down in order to take retirement at the end...

Article: Market access in Brazil

All eyes on Spinraza

China: How to strategise and win in the world’s fastest changing healthcare market

In this paper, experts Marc Yates, Pei Li Teh and Brett Gardiner discuss the China healthcare reforms which affect pharma and propose how to build the market understanding required to launch...

Infographic: Preparing to launch a new asset and in need of demand assessment research?

Download our pre-launch checklist

Article: Engaging patient advocacy groups

The key to conducting effective rare disease research

Webcast: Harnessing the power of social: How to generate fresh insights for your business using social media listening

Download our third Innovation in #MRX webcast, hosted in partnership with Convosphere, where we discuss how to use social media listening to answer key business questions.Watch here: https://bit.ly/2nM0xvj

Article: Like, Like, Like: Harnessing the power of social media insights

Given the colossal amount of personal and professional information that we share online, social media channels such as Facebook and Twitter are fast becoming treasure troves of big data. As...

Infographic: China: How to keep up and win in the world’s fastest changing healthcare market

Our latest infographic outlines the changes to the clinical trial process, accelerated drug approval, fast track of rare disease products and access opportunities in China's evolving healthcare environment.Find out more here-...